Merus (NASDAQ:MRUS) Given Consensus Rating of "Buy" by Analysts

Shares of Merus (NASDAQ:MRUS - Get Free Report) have received an average rating of "Buy" from the sixteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Fourteen equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $85.92.

Several equities analysts have recently commented on MRUS shares. Needham & Company LLC restated a "buy" rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, December 9th. The Goldman Sachs Group initiated coverage on Merus in a report on Thursday, November 21st. They issued a "buy" rating and a $73.00 price target on the stock. Wells Fargo & Company began coverage on shares of Merus in a report on Friday, February 7th. They set an "overweight" rating and a $91.00 price objective for the company. Citigroup lifted their price objective on shares of Merus from $89.00 to $97.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Finally, Guggenheim restated a "buy" rating on shares of Merus in a research report on Wednesday, February 12th.

Institutional Investors Weigh In On Merus

Several large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in shares of Merus in the 4th quarter worth approximately $60,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Merus by 17.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company's stock worth $4,152,000 after buying an additional 14,544 shares during the last quarter. Woodline Partners LP boosted its stake in Merus by 0.3% during the fourth quarter. Woodline Partners LP now owns 1,188,518 shares of the biotechnology company's stock worth $49,977,000 after buying an additional 3,593 shares during the period. Squarepoint Ops LLC purchased a new position in Merus during the fourth quarter worth $817,000. Finally, Wexford Capital LP increased its position in Merus by 26.2% during the fourth quarter. Wexford Capital LP now owns 40,386 shares of the biotechnology company's stock valued at $1,698,000 after acquiring an additional 8,386 shares during the last quarter. 96.14% of the stock is owned by institutional investors.

Merus Trading Up 6.6 %

Shares of MRUS traded up $2.80 during trading hours on Friday, reaching $45.07. 577,549 shares of the stock traded hands, compared to its average volume of 577,274. The company has a market cap of $3.09 billion, a P/E ratio of -11.41 and a beta of 1.11. The company's 50-day moving average price is $41.48 and its two-hundred day moving average price is $47.05. Merus has a 52-week low of $37.77 and a 52-week high of $61.61.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.